Soleno Therapeutics INC

SolenO Therapeutics, Inc. has been acquired by Neurocrine Biosciences, Inc. through a tender offer and subsequent merger, with shareholders receiving $53.00 per share.

Soleno Therapeutics has voluntarily withdrawn its European marketing application for VIOKAT, a treatment for Prader-Willi syndrome, citing strategic business reasons.

Neurocrine Biosciences has entered into a definitive agreement to acquire Soleno Therapeutics for $53.00 per share in cash.

Soleno Therapeutics, Inc. has adopted amended and restated bylaws to update stockholder advance notice provisions, reflect Delaware law changes, and include a forum selection clause.

Soleno Therapeutics announced the appointment of Jennifer Fulk as its new Chief Financial Officer, succeeding James Mackaness who will retire by the end of March 2026.

Soleno Therapeutics reported strong fourth quarter and full-year 2025 financial results, achieving profitability and significant progress in the U.S. launch of VYKAT XR for Prader-Willi syndrome.

Soleno Therapeutics announces significant revenue growth and profitability in Q1 2026, driven by VYKAT XR sales, while also entering into a merger agreement with Neurocrine Biosciences.

Soleno Therapeutics achieved profitability in Q3 2025 driven by strong initial sales of its newly FDA-approved drug VYKAT XR for Prader-Willi syndrome, despite a net loss for the nine-month period.

Soleno Therapeutics, Inc. announced its first product revenue of $32.7 million from VYKAT XR sales following FDA approval, significantly reducing its net loss for the quarter.

Soleno Therapeutics announces its first quarter 2025 results, highlighting the FDA approval and initial prescriptions of VYKAT XR for Prader-Willi syndrome.

Soleno Therapeutics' Q3 2024 report reveals a significant increase in operating expenses, primarily driven by research and development and general and administrative costs, as the company advances its lead drug candidate, DCCR, towards potential FDA approval.

Soleno Therapeutics reports a net loss of $43.3 million for the first half of 2024, driven by increased research and development and general administrative expenses, while also submitting a New Drug Application (NDA) for its lead candidate.

Soleno Therapeutics files an amendment to its 2025 Annual Report to include required Part III disclosures regarding corporate governance and executive compensation.

Soleno Therapeutics, Inc. reported its first profitable year in 2025, driven by $190.4 million in VYKAT XR sales following its FDA approval for Prader-Willi syndrome.

Soleno Therapeutics awaits a critical FDA decision in March 2025 for its DCCR drug targeting hyperphagia in Prader-Willi syndrome, while navigating financial losses and building its commercial infrastructure.

Soleno Therapeutics' 10-K filing details the company's financials, clinical trial progress, and plans for its lead drug candidate, DCCR, targeting Prader-Willi syndrome.

Kristen Yen, SVP Global Clinical Operations at Soleno Therapeutics, reports transactions related to the company's merger with Neocrine Biosciences.

Soleno Therapeutics' Director Birgitte Volck reports changes in beneficial ownership following the company's merger with Neocrine Biosciences.

Soleno Therapeutics, Inc. has completed its merger with Neocrine Biosciences, Inc., resulting in changes to executive beneficial ownership of securities.

Soleno Therapeutics, Inc. announced the completion of its merger with Neocrine Biosciences, Inc., with executive Matthew Pauls reporting changes in beneficial ownership.

Soleno Therapeutics, Inc. reports on executive ownership changes following its merger with Neocrine Biosciences, Inc.

Meredith Manning, Chief Commercial Officer of Soleno Therapeutics, reports significant changes in beneficial ownership following the company's merger with Neocrine Biosciences.

Soleno Therapeutics will hold its annual stockholder meeting virtually on June 5, 2025, to elect directors and ratify the appointment of its accounting firm.

Soleno Therapeutics announces FDA approval of VYKAT XR for Prader-Willi syndrome and sets the date for its annual stockholders meeting on June 5, 2025.

Soleno Therapeutics is holding its annual meeting on June 6, 2024, to vote on the election of a director, ratification of its accounting firm, and approval of an amended equity incentive plan.

T. Rowe Price Associates, Inc. has filed a Schedule 13G, reporting beneficial ownership of 2.0% of Soleno Therapeutics Inc.'s common stock as of March 31, 2026.

Avoro Capital Advisors LLC and Behzad Aghazadeh have reported beneficial ownership of 4.45% of Soleno Therapeutics Inc. common stock as of March 31, 2026.

Wellington Management Group LLP and its affiliates have reported beneficial ownership of 8.6% of Soleno Therapeutics, Inc. common stock as of March 31, 2026.

State Street Corporation has reported beneficial ownership of 5.2% of Soleno Therapeutics Inc.'s common stock as of March 31, 2026.

Janus Henderson Group plc has reported beneficial ownership of 1,205,303 common shares, representing 2.3% of the class, in Soleno Therapeutics, Inc. as of April 30, 2026.

FMR LLC, through its subsidiaries, has disclosed a beneficial ownership of 0.4% of Soleno Therapeutics Inc.'s common stock as of April 30, 2026.